Mã QR

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan

Introduction: On the basis of the IMpower133 trial, atezolizumab plus carboplatin and etoposide (CE) is approved as first-line treatment for extensive-stage (ES)-SCLC. The J-TAIL-2 study evaluated atezolizumab plus CE in routine clinical practice settings. Methods: J-TAIL-2 was a prospective, multic...

Mô tả đầy đủ

Đã lưu trong:
Những tác giả chính: Eisaku Miyauchi, MD, PhD, Makoto Nishio, MD, PhD, Kadoaki Ohashi, MD, PhD, Atsushi Osoegawa, MD, PhD, Eiki Kikuchi, MD, PhD, Hideharu Kimura, MD, PhD, Yasushi Goto, MD, PhD, Junichi Shimizu, MD, PhD, Hiroshige Yoshioka, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Nobuyuki Katakami, MD, PhD, Masahide Oki, MD, PhD, Takashi Kijima, MD, PhD, Kenichi Chikamori, MD, PhD, Kazumi Nishino, MD, PhD, Yuki Kobayashi, MS, Asako Miwa, BA, Misa Tanaka, MS, Akihiko Gemma, PhD
Định dạng: Artigo
Ngôn ngữ:Inglês
Được phát hành: Elsevier 2025-03-01
Loạt:JTO Clinical and Research Reports
Những chủ đề:
Extensive-stage small cell lung cancer
Atezolizumab
Immune checkpoint inhibitor
Observational study
Truy cập trực tuyến:http://www.sciencedirect.com/science/article/pii/S266636432400153X
Các nhãn: Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Những quyển sách tương tự